NasdaqGS:GILD - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	31,560	9,628	13,193	12,246	22
12/31/2026	30,120	8,946	12,658	11,602	27
12/31/2025	29,210	8,283	10,767	10,533	25
9/30/2025	29,087	8,110	9,162	9,667	N/A
6/30/2025	28,863	6,311	9,369	9,868	N/A
3/31/2025	28,735	5,965	9,844	10,366	N/A
12/31/2024	28,754	480	10,305	10,828	N/A
9/30/2024	28,299	126	9,431	10,022	N/A
6/30/2024	27,805	1,054	6,896	7,468	N/A
3/31/2024	27,450	485	7,900	8,481	N/A
12/31/2023	27,116	5,665	7,421	8,006	N/A
9/30/2023	27,391	5,876	7,853	8,404	N/A
6/30/2023	27,382	5,484	8,926	9,512	N/A
3/31/2023	27,043	5,583	8,386	8,976	N/A
12/31/2022	27,281	4,592	8,344	9,072	N/A
9/30/2022	27,136	3,334	9,007	9,710	N/A
6/30/2022	27,515	4,137	9,415	10,100	N/A
3/31/2022	27,472	4,515	9,953	10,614	N/A
12/31/2021	27,305	6,225	10,805	11,384	N/A
9/30/2021	27,482	7,394	9,491	10,095	N/A
6/30/2021	26,638	5,162	8,472	9,092	N/A
3/31/2021	25,564	301	8,698	9,342	N/A
12/31/2020	24,689	123	7,518	8,168	N/A
9/30/2020	23,147	1,268	8,160	8,832	N/A
6/30/2020	22,174	-257	8,510	9,227	N/A
3/31/2020	22,716	4,962	8,244	9,003	N/A
12/31/2019	22,449	5,386	8,319	9,144	N/A
9/30/2019	22,365	2,693	8,039	8,909	N/A
6/30/2019	22,357	5,955	N/A	8,476	N/A
3/31/2019	22,320	5,892	N/A	7,707	N/A
12/31/2018	22,127	5,455	N/A	8,400	N/A
9/30/2018	22,281	1,587	N/A	8,808	N/A
6/30/2018	23,197	2,208	N/A	9,290	N/A
3/31/2018	24,690	3,464	N/A	11,243	N/A
12/31/2017	26,107	4,628	N/A	11,898	N/A
9/30/2017	27,478	11,601	N/A	12,684	N/A
6/30/2017	28,466	12,213	N/A	14,383	N/A
3/31/2017	29,101	12,637	N/A	15,842	N/A
12/31/2016	30,390	13,501	N/A	17,047	N/A
9/30/2016	31,576	15,076	N/A	18,382	N/A
6/30/2016	32,371	16,346	N/A	18,085	N/A
3/31/2016	32,839	17,341	N/A	18,758	N/A
12/31/2015	32,639	18,108	N/A	21,250	N/A
9/30/2015	31,447	16,912	N/A	18,476	N/A
6/30/2015	29,194	15,043	N/A	18,424	N/A
3/31/2015	27,485	14,207	N/A	16,951	N/A
12/31/2014	24,890	12,101	N/A	12,818	N/A

アナリストによる今後の成長予測

収入対貯蓄率: GILDの予測収益成長率 (年間7.4% ) は貯蓄率 ( 3.3% ) を上回っています。

収益対市場: GILDの収益 ( 7.4% ) US市場 ( 16.2% ) よりも低い成長が予測されています。

高成長収益: GILDの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: GILDの収益 ( 3.8% ) US市場 ( 10.7% ) よりも低い成長が予測されています。

高い収益成長: GILDの収益 ( 3.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GILDの自己資本利益率は、3年後には高くなると予測されています ( 34.3 %)

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/12/24 04:24
終値	2025/12/24 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Gilead Sciences, Inc. 27 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。67

アナリスト	機関
David Toung	Argus Research Company
Brian Skorney	Baird
James Birchenough	Barclays

Gilead Sciences 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates increase by 15%

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2025

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2025

Consensus EPS estimates fall by 27%

Consensus EPS estimates fall by 36%

Price target increased by 7.6% to US$94.62

Recent updates

Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ARTISTRY-2 Trial

Upcoming dividend of US$0.79 per share

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025

Gilead Sciences, Inc. Joins Partners for Delivery of First Shipments of Breakthrough Twice-Yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Executive VP of Corporate Affairs exercised options and sold US$3.1m worth of stock

Gilead Sciences, Inc.'s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ART-1 Trial

Gilead Sciences, Inc. Provides Update on Phase 3 ASCENT-07 Study

Consensus EPS estimates increase by 15%

Third quarter dividend of US$0.79 announced

Gilead Sciences, Inc. announces Quarterly dividend, payable on December 30, 2025

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2025

Gilead Sciences, Inc. to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (Pbc) and Investigational Bulevirtide in Chronic Hepatitis Delta

Gilead Sciences, Inc. Receives Health Canada Approval for the Treatment of Primary Biliary Cholangitis

Gilead Sciences, Inc. to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

Gilead Presents New Hiv Research Data At EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care with New Data At Esmo 2025

Gilead Sciences, Inc. to Report Q3, 2025 Results on Oct 30, 2025

Upcoming dividend of US$0.79 per share

Gilead Sciences, Inc. Announces European Commission Authorizes Twice-Y Early Yeytuo (Lenacapavir) for HIV Prevention

Chief Commercial Officer notifies of intention to sell stock

Second quarter dividend of US$0.79 announced

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.

Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?

Gilead Receives Positive CHMP Opinions Under Accelerated Review from European Medicines Agency for Twice-Yearly HIV PrEP Option in the European Union

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention At Ias 2025

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure Prophylaxis

Upcoming dividend of US$0.79 per share

Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Chief Commercial Officer notifies of intention to sell stock

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of Trodelvy

Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are

Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025

Gilead Sciences, Inc. to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

First quarter dividend of US$0.79 announced

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance

Gilead Sciences, Inc. Declares Quarterly Dividend for the Second Quarter of 2025, Payable on June 27, 2025

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-04/KeyNOTE-D19 Study

Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price

Gilead Sciences, Inc. to Report Q1, 2025 Results on Apr 24, 2025

New HIV, Livdelzi And CAR T Options Will Expand Reach

Gilead Sciences, Inc., Annual General Meeting, May 07, 2025

Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally

Chairman & CEO exercised options and sold US$1.4m worth of stock

Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy Option

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Gilead Sciences, Inc. Presents the First Data from Its Ongoing Phase 1 Study Investigating Two Novel, Once-Yearly Formulations of Lenacapavir

Upcoming dividend of US$0.79 per share

Why Gilead Sciences Remains A Buy After A 40% Rally

European Medicines Agency Validates Gilead's Marketing Authorization Application and Eu-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv Prevention

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Gilead Sciences, Inc. Announces U.S. FDA Acceptance of Its New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

Chief Financial Officer exercised options and sold US$4.8m worth of stock

Fourth quarter dividend increased to US$0.79

New minor risk - Financial position

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2025

Gilead Sciences: Diversification Strategy Not Derisked Enough Yet

Gilead Sciences (NASDAQ:GILD) Could Easily Take On More Debt

Gilead: Strong Sales Growth Remains With Veklury And Beyond

Gilead Sciences, Inc. to Report Q4, 2024 Results on Feb 11, 2025

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Consensus EPS estimates fall by 27%